share_log

Clearmind Medicine | 6-K: Report of foreign private issuer (related to financial reporting)

Clearmind Medicine | 6-K: Report of foreign private issuer (related to financial reporting)

Clearmind Medicine | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/09/17 04:07

Moomoo AI 已提取核心信息

Clearmind Medicine reported significant progress in Q3 2024, receiving FDA clearance for its Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder treatment. The multinational trial will be conducted at Yale, Johns Hopkins, and Israel's IMCA. The company completed a $2.4M registered direct offering in January 2024 to support operations.The company expanded its intellectual property portfolio through strategic licensing agreements with Hebrew University and Bar-Ilan University for novel psychedelic compounds targeting PTSD and cocaine addiction. Additionally, Clearmind advanced its MEAI-based alcohol substitute beverage program, completing pre-clinical studies for novel-food application and securing manufacturing partnerships.For Q3 2024, Clearmind reported a net loss of $2.09M compared to $575K in Q3 2023, with research costs of $346K and G&A expenses of $1.13M. The company maintained a strong financial position with $7.68M in cash as of July 31, 2024, providing sufficient liquidity for at least twelve months of operations.
Clearmind Medicine reported significant progress in Q3 2024, receiving FDA clearance for its Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder treatment. The multinational trial will be conducted at Yale, Johns Hopkins, and Israel's IMCA. The company completed a $2.4M registered direct offering in January 2024 to support operations.The company expanded its intellectual property portfolio through strategic licensing agreements with Hebrew University and Bar-Ilan University for novel psychedelic compounds targeting PTSD and cocaine addiction. Additionally, Clearmind advanced its MEAI-based alcohol substitute beverage program, completing pre-clinical studies for novel-food application and securing manufacturing partnerships.For Q3 2024, Clearmind reported a net loss of $2.09M compared to $575K in Q3 2023, with research costs of $346K and G&A expenses of $1.13M. The company maintained a strong financial position with $7.68M in cash as of July 31, 2024, providing sufficient liquidity for at least twelve months of operations.
Clearmind Medicine在2024年第三季度报告了显著进展，获得FDA批准进行CMND-100治疗酒精使用障碍的I/IIa期临床试验。该多国试验将在耶鲁大学、约翰霍普金斯大学以及以色列的IMCA进行。公司在2024年1月完成了一项240万美元的注册直接发行，以支持运营。公司通过与希伯来大学和巴伊兰大学签署战略许可协议，扩展了其知识产权组合，开发针对创伤后应激障碍(PTSD)和可卡因成瘾的新型致幻化合物。此外，Clearmind推进了基于MEAI的酒精替代饮料项目，完成了新食品申请的临床前研究，并获得了制造合作伙伴。在2024年第三季度，Clearmind报告净亏损为209万美元，相较于2023年第三季度的57.5万美元，研究成本为34.6万美元，管理和一般(G&A)费用为113万美元。公司在2024年7月31日保持了强劲的财务状况，现金余额为768万美元，为至少十二个月的运营提供了足够的流动性。
Clearmind Medicine在2024年第三季度报告了显著进展，获得FDA批准进行CMND-100治疗酒精使用障碍的I/IIa期临床试验。该多国试验将在耶鲁大学、约翰霍普金斯大学以及以色列的IMCA进行。公司在2024年1月完成了一项240万美元的注册直接发行，以支持运营。公司通过与希伯来大学和巴伊兰大学签署战略许可协议，扩展了其知识产权组合，开发针对创伤后应激障碍(PTSD)和可卡因成瘾的新型致幻化合物。此外，Clearmind推进了基于MEAI的酒精替代饮料项目，完成了新食品申请的临床前研究，并获得了制造合作伙伴。在2024年第三季度，Clearmind报告净亏损为209万美元，相较于2023年第三季度的57.5万美元，研究成本为34.6万美元，管理和一般(G&A)费用为113万美元。公司在2024年7月31日保持了强劲的财务状况，现金余额为768万美元，为至少十二个月的运营提供了足够的流动性。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Channel Therapeutics
    CHRO
    -- 1.900
    泰坦制药
    TTNP
    -- 3.8350
    LakeShore Biopharma
    LSB
    -- 2.723
    Rigel Pharmaceuticals
    RIGL
    -- 20.130
    Veru Inc
    VERU
    -- 0.975

    解锁榜首股票

    热门讨论
    特朗普2.0时代倒计时！全球股市的下一个风口？
    🎙️️讨论： 1. 加密货币政策能否利好crypto？ 2. 关税政策能否利好中概等海外资产？ 展开
    特朗普2.0机会预览：在总统上任前猜出市场赢家！